Enliven Therapeutics

NSQ:ELVN · US29337E1029

PharmaceuticalsSmall

360° View

Value19

Price/Sales1

Price/Earnings91

Price/Book33

Dividend Yield1

Growth24

Revenue Growth—

Profit Growth41

Capital Growth4

TSR 52w61

Safety85

Leverage100

Liquidity24

Refinancing74

Combined40

Sentiment100

Analyst Opinions100

Pro Holdings79

Opinion Changes90

Market Pulse82

Profile

CountryUSA

IndustryPharmaceuticals

SizeSmall

TypePublic Company

ExchangeNASDAQGS

Employees57

Websiteenliventherapeutics.com

ISINUS29337E1029

Last UpdateApr 2, 2026

Index & Theme

HematologyChronic DiseasesCentral Nervous SystemOncologyBiotechnologyLife ScienceTherapeutics

Description

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. The company is advancing ELVN-001, as well as pursu…

Analysis

Enliven Therapeutics's 360° View rank of 62 places it above its peer average — better than 62% of its true peers.

It's lagging on growth (24) and expensive versus peers (19). On safety it is very well financed (85), and the market shows strongly positive sentiment (100). Taken together, its Combined rank of 40 reads as below its peer average.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Enliven Therapeutics with its peers

Cognition Therapeutics

NAQ:CGTX

—

CountryUSA

IndustryPharmaceuticals

SizeX-Small

Full Stock Analysis →

Terns Pharmaceuticals

NSQ:TERN

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Nektar

NAQ:NKTR

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Contineum Therapeutics

NSQ:CTNM

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

MBX Biosciences

NSQ:MBX

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

BIOAGE Labs

NSQ:BIOA

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →